Spero therapeutics announces new strategic direction focusing on advancing promising clinical-stage pipeline

Announces immediate cessation of tebipenem hbr commercialization initiatives; company to shift focus to advancement of spr720 and spr206

SPRO Ratings Summary

SPRO Quant Ranking